02043QAB3
Alnylam Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes RNAi therapeutics — medicines that "silence" disease-causing genes — with six marketed drugs including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO for rare conditions like ATTR amyloidosis. Founded in 2002 by Nobel laureate Phillip Sharp and fellow scientists, its name comes from Alnilam, the bright center star of Orion's belt, chosen as an "aspirational North Star" for genomic medicine. Its ONPATTRO was the first RNAi drug ever approved by the FDA, in 2018.
CONVERTIBLEUnderlying: ALNYCUSIP: 02043QAB3HealthcareUS1 derivative reporter
1.00% Convertible Senior Notes due September 15, 2027
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
